Cargando…
Validity of Urinary Monoamine Assay Sales Under the “Spot Baseline Urinary Neurotransmitter Testing Marketing Model” [Expression of Concern]
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192579/ https://www.ncbi.nlm.nih.gov/pubmed/32425578 http://dx.doi.org/10.2147/IJNRD.S240218 |
Ejemplares similares
-
Validity of urinary monoamine assay sales under the “spot baseline urinary neurotransmitter testing marketing model”
por: Hinz, Marty, et al.
Publicado: (2011) -
Urinary Neurotransmitter Testing: Considerations of Spot Baseline Norepinephrine and Epinephrine [Expression of Concern]
Publicado: (2020) -
Validity of Urinary Monoamine Assay Sales Under the “Spot Baseline Urinary Neurotransmitter Testing Marketing Model” [Retraction]
Publicado: (2021) -
The Discrediting of the Monoamine Hypothesis [Expression of Concern]
Publicado: (2020) -
Monoamine Depletion by Reuptake Inhibitors [Expression of Concern]
Publicado: (2020)